
Kennedy's Allies Against Pesticides: Environmentalists, Moms and Manly Men
In Europe, the weedkiller atrazine has been banned for nearly two decades because of its suspected links to reproductive problems like reduced sperm quality and birth defects.
In the United States, it remains one of the most widely used pesticides, sprayed on corn, sugar cane and other crops, the result of years of industry lobbying. It has been detected in the drinking water of some 40 million Americans.
Now, American environmental groups that have long sought a ban are finding some unexpected allies: the Trump administration and its MAGA supporter base.
This week, a 'Make America Healthy Again' commission led by Health and Human Services Secretary Robert F. Kennedy Jr. is set to issue a report on the causes of chronic illnesses in the United States. And Mr. Kennedy, who worked for years as an environmental lawyer fighting chemical companies, wants the report to highlight the harms of pesticides like atrazine, according to three people with knowledge of his efforts.
It is an unwieldy coalition, extending even to some men's rights influencers on alternative media, where commentary abounds on how toxic chemicals are threatening masculinity.
They are taking on an influential agricultural and chemicals lobby that has long rebuffed attempts to strengthen restrictions on atrazine and other pesticides, at a time when the Trump administration is rolling back government restrictions on industries, not imposing new ones.
Mr. Kennedy has a vocal movement behind him.
'We're calling for a ban of 85 pesticides that have already been banned in other countries,' said Zen Honeycutt, who leads a coalition of mothers opposed to pesticides and genetically modified organisms, at a national conference of Make America Healthy Again supporters ahead of the report's publication.
'These pesticides cause reproductive damage, and we have a reproductive crisis in our country today,' she said at the meeting, attended by farmers, health influencers and conservative activists, as well as several administration officials. 'Do we want the American population to be able to procreate or not?'
Lori Ann Burd, senior attorney at the Center for Biological Diversity, a group that has long sought a ban in the United States of atrazine and other pesticides, sees an uneasy but potentially powerful alignment of interests.
'There's an epic battle brewing over the direction that the administration is going to take on toxic chemicals,' she said. 'This is the movement that helped to elect Trump,' she said. 'But we're also up against some of the most powerful corporate lobby groups in the country.'
The showdown is the latest chapter in a long battle over pesticides like atrazine, long valued for its efficacy and affordability in controlling weeds and increasing crop yields. Each year, American farmers spray the pesticide on about 75 million acres of farmland, roughly equivalent to the area of New Mexico.
But atrazine can also run off into streams and rivers, contaminating water sources and harming aquatic life. In humans, it is an endocrine disruptor linked to preterm delivery, birth defects and low sperm counts, and possibly to thyroid, ovarian, and other cancers. Some sixty countries ban the use of atrazine, manufactured by Switzerland-based Syngenta, which was acquired by the Chinese state-owned chemical company ChemChina in 2017.
Syngenta did not immediately respond to a request for comment.
The federal agency led by Mr. Kennedy, Health and Human Services, referred questions to the White House, which declined to comment.
In America, the farming lobby has fought attempts to regulate the chemical. During the first Trump administration, the Environmental Protection Agency rolled back restrictions on the use of several pesticides, including atrazine. That rollback came under Nancy Beck, a former chemical-industry lobbyist who at that time led the agency's toxic chemicals program.
Today, Ms. Beck is back at the E.P.A. as principal deputy assistant administrator overseeing the Office of Chemical Safety. In recent weeks she has pushed back against mentioning pesticides in the MAHA commission report, according to the three people with knowledge of the commission's discussions.
Kailee Tkacz Buller, a former seed oil lobbyist who is chief of staff at the Department of Agriculture, has also pushed back against focusing on pesticides in the MAHA report, citing concerns over disruptions to the food supply chain, one of the three people said.
That came after 79 Republican senators, led by Pete Ricketts of Nebraska, urged the Trump administration to resist efforts from 'activist groups promoting misguided and sometimes malicious policies masquerading as health solutions.' In their letter, the Republican lawmakers accused environmental activists of all stripes of 'advancing harmful health, economic or food security policies under the guise of human health.'
On Tuesday, a coalition of farm groups, including the National Corn Growers Association, issued a statement urging the Trump administration to 'consider the consequences' of a report that suggested U.S. farmers were harming Americans through their production practices.
'We urge President Trump to ensure that the MAHA Commission report is based on sound science and evidence-based claims rather than opinions and preferences of social influencers and single-issue activists with little to no experience in actual farming or food production,' the groups said.
MAHA supporters are unfazed.
'Big Ag, Big Food, Big Pharma, the pesticide companies, all of these companies are the delivery mechanisms for toxins,' said Tony Lyons, co-president of the newly established MAHA Institute, which hosted the MAHA conference. 'Our government agencies shouldn't be protecting a handful of the most powerful companies on earth, protecting their profits over the welfare of its own citizens.'
MAHA advocates say recent remarks from Mr. Trump and Mr. Kennedy signal a different approach under the second Trump administration.
Since allying with Mr. Kennedy, Mr. Trump has complained about how the United States spends 'billions and billions of dollars on pesticides,' compared to the European Union, yet has worse health outcomes. He has pledged that his administration would 'ensure that everybody will be protected from harmful chemicals, pollutants, pesticides.' Mr. Kennedy is looking into pesticides seriously, Mr. Trump said, 'because maybe it's not necessary to use all of that.'
For his part, Mr. Kennedy has repeatedly called atrazine 'extraordinarily toxic' and has said that pesticides are significant contributors to chronic health problems and cancer.
The anti-pesticide cause is finding supporters among online commentators who speak out on issues they consider important to men, such as infertility.
'There has never been an era in human history where men are losing more. More men than ever are infertile,' Jackson Hightower, a men's health influencer with more than a million followers across various social platforms, said in a recent video. 'No one seems to be talking about how a major contributing factor to this is our food supply. And we have so much evidence to support the dangers of spraying our crops with chemicals like atrazine.'
Research has shown there is some evidence globally of declining fertility among men. Studies have pointed to numerous factors that could be causing a decline, including chemical exposure and lifestyle choices like alcohol consumption, poor diet and lack of physical activity.
Calley Means, an adviser to Mr. Kennedy who played a key role in orchestrating his endorsement of Mr. Trump, said he believed the country was 'seeing one of the most significant realignments in American politics in American history.' He is the brother of Dr. Casey Means, Mr. Trump's nominee for Surgeon General and another Kennedy ally.
'We've galvanized a movement of moms, of independents, of young people,' Mr. Means said, 'a revolutionary coalition of people who are going to change American politics.'
All of this is happening as the Trump administration pursues a deregulatory drive that has few parallels in American history. The E.P.A., under Administrator Lee Zeldin, is revising or repealing more than 30 regulations aimed at protecting the air, water and Earth's climate.
There is also the question of how much influence Mr. Kennedy, as health secretary, can have over pesticide policy. Though the Federal Drug Administration, which is under his agency, can regulate pesticide residues in food, it is a different agency, the E.P.A., that regulates pesticide use.
The E.P.A. is currently updating its mitigation proposals for atrazine, including revising its levels of concern for atrazine in water. But whether pesticides are targeted in the MAHA commission report, set to be issued on Thursday, is seen as an early test of the government's approach. The report is expected to be a broad overview of the potential causes of chronic disease in children, including chemical exposures, food, lack of exercise and too much screen time.
'I think if President Trump stands up and gets this out to the American people, he will go down as a historical figure who changed the trajectory of chronic disease,' said Vani Hari, widely known as the Food Babe, a popular author and activist close to Mr. Kennedy.
The E.P.A. said in a statement that the Trump administration was 'having robust conversations across government about how to drive economic growth while protecting human health and the environment.' The agency pointed to Dr. Beck's extensive civil service career before her time working as an industry lobbyist, saying Mr. Trump had made 'a fantastic choice' in selecting her to work at the agency.
Traditional environmentalists, meanwhile, remain wary of MAHA's controversial positions on lifesaving vaccines and more.
As health secretary, Mr. Kennedy has broken with his predecessors by not advocating for vaccination, for example casting the decision to vaccinate against measles as a personal one. During an appearance last month by Mr. Kennedy at a conference focused on solving the global plastic trash crisis, environmentalists said they had steered him away from talk of vaccines.
Even on pesticides, Mr. Kennedy's scientific justifications aren't always sound. He has suggested that chemicals in the water might be responsible for 'sexual dysphoria' in children. In a segment aired by CNN, he said that atrazine could 'forcibly feminize' frogs. 'What this does to sexual development in children, nobody knows,' he said.
(While there is research on atrazine feminizing male frogs, there is no evidence that the chemical similarly affects humans.)
Jay Feldman, executive director of the environmental advocacy group Beyond Pesticides, said he hoped Mr. Kennedy's unorthodox claims did not undermine the effort to regulate pesticides. For years he worked alongside Mr. Kennedy to raise awareness of the risks of pesticide exposure.
'It's unfortunate when you have an active player who has been a leading voice on environmental protection for most of his life attach himself to something so controversial,' he said. 'The question is, will everything he does now be dismissed?'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
11 minutes ago
- Medscape
CKD Therapy Unchanged by Patient and PCP Nudge Letters
VIENNA — Sending 'nudge' letters to patients with chronic kidney disease (CKD) or their general practitioners had no impact on their likelihood of receiving guideline-directed medical care, suggested a prescription analysis of over 22,000 Danish adults with CKD. METHODOLOGY: NUDGE-CKD included all Danish individuals aged 18 years or older on August 19, 2024, who had received a diagnosis of CKD in the previous 5 years during at least one hospital encounter and who were enrolled in the Danish governmental electronic letter system, which has 95% coverage. It also included all Danish general practices contactable via electronic letter that had at least one patient with CKD on their list. For patients, the letter highlighted the potential benefits of kidney and heart health and encouraged a discussion of treatment options, while for general practitioners, the letter focused on the latest treatment guidelines. In the patient arm of the study, 22,627 individuals were randomly assigned to receive a letter (n = 11,223) or no letter (n = 11,394). The average age was 71 years, and approximately 36% were women. For the practitioner arm, 1540 general practices, caring for 28,069 patients with CKD, were assigned to receive a letter (774 practices caring for 13,959 patients) or usual care (766 practices caring for 14,110 patients). The average patient age was 73 years, and approximately 39% were women. Both patients and practices were followed up for 6 months (until February 19, 2025), with the primary endpoint the number of filled prescriptions for a renin-angiotensin system inhibitor (RASi) or SGLT2 inhibitor (SGLT2i). TAKEAWAY: The patient analysis revealed that there was no significant difference in prescriptions of RASi or SGLT2i between those who received a nudge letter and those who did not, at a relative risk of 0.99 ( P = .21). = .21). Very similar results were seen on the general practice analysis, at a relative risk of a RASi or SGLT2i prescription with a nudge letter vs usual care of 0.99 ( P = .41). = .41). No significant differences were seen on the subgroup analysis and when looking at the time to prescription for new users, and there was no interaction between the patient and general practice results ( P = .85). IN PRACTICE: The trial was the 'largest provider-targeted implementation study to date evaluating a scalable, low-cost strategy to improve the use of guideline-related medical therapy in CKD' and the 'first large-scale trial of a digitally delivered strategy targeting patients with a common chronic condition,' said the study presenter. 'While the results were neutral, they may provide valuable insights for future efforts,' he concluded. SOURCE: The research was conducted by Kristoffer Grundtvig Skaarup, MD, Department of Cardiology, Copenhagen University Hospital — Herlev and Gentofte, Denmark, and colleagues, and described over two presentations at the 62nd European Renal Association (ERA) Congress 2025 on June 7. LIMITATIONS: Skaarup pointed out that, on the general practice side, the intervention was a 'one-time letter…and not linked to specific patients, which may have limited its lasting impact.' He suggested that more integrated approaches timed to clinical encounters or even embedded into existing clinical workflows closer to when prescription decisions are made may be more effective in primary care. Although most patients reported reading the letter, Skaarup said that few acted on it, potentially due to its general, non-personalized content, with no explicit medical therapy recommendations, which may limit its perceived relevance or urgency. DISCLOSURES: No external funding was obtained for the trial. Skaarup received funding through a research grant from the Danish Cardiovascular Academy, which is supported by the Novo Nordisk Foundation and the Danish Heart Foundation. No relevant financial relationships were declared. Liam Andrew Davenport, MA (Hons), is a UK-based medical journalist and writer with more than 20 years' experience. He studied medical sciences and anthropology at Emmanuel College, Cambridge, England.
Yahoo
19 minutes ago
- Yahoo
Musk says he regrets some posts he made about Trump
(Reuters) -Billionaire Elon Musk said on Wednesday that he regrets some of the posts he made last week about U.S President Donald Trump, in a message on his social media platform X. "I regret some of my posts about President Donald Trump last week. They went too far," Musk wrote. Trump and Musk began exchanging insults last week on social media, with the Tesla and SpaceX CEO describing the president's sweeping tax and spending bill as a "disgusting abomination." Musk's post comes days after Trump said his relationship with Musk was over.
Yahoo
19 minutes ago
- Yahoo
The cheap fat jabs sending big pharma into a frenzy
For many Americans who tuned in to watch the Super Bowl earlier this year, it was a surprise to find themselves fat-shamed during the ad break. 'Obesity is America's deadliest epidemic,' a voiceover said, as images of wobbling bellies, greasy burgers and giant apple pies flashed across TV screens. The Super Bowl's 127m-strong audience, who were tucking into an estimated 1.5bn chicken wings during the event, were warned that 'obesity leads to half a million deaths each year'. But Hims and Hers, the US online medicines company behind the ad, said people should not blame themselves. Instead, its advert claimed that 'the system' was keeping them 'sick and stuck', adding that 'there are medications that work, but they're priced for profits, not patients'. To the relief of viewers, Hims and Hers offered a 'life-changing' solution. Rather than paying hundreds of dollars each month for well-known, branded weight-loss jabs such as Wegovy, households could instead try Hims and Hers' cheaper, replica versions. 'This is the future of healthcare,' it argued. 'Join us in the fight for a healthier America.' However, for the likes of Danish obesity drug maker Novo Nordisk and US pharma rival Eli Lilly, which have claimed the rise of copycat jabs poses potential health risks, such claims have become a serious headache. Over the past few decades, both businesses have poured billions of dollars into obesity drug research – recently yielding blockbuster drugs Wegovy and Mounjaro. The rapid uptake of such drugs has prompted a surge in revenues for big pharma. But bosses are now increasingly worried that demand among American patients has been dented by a cluster of smaller, copycat companies. According to industry estimates from November, around a quarter of the 8m Americans on weight-loss drugs were taking knock-off replica versions. These medicines, known as 'compound' drugs, were priced at around $200 ($148) a month, compared to over $1,300 for some branded versions. Barclays analyst Emily Field says the boom in copycat weight-loss drugs has been a 'unique phenomenon' in the US, sparking an inevitable surge in legal claims that has drawn the attention of regulators. So-called compound drugs are essentially custom-made medicines created by pharmacies using the same active ingredients of patented drugs. Historically, compounding pharmacies create custom versions of medicines if they need to personalise them for patients. For example, if someone is unable to take a standard oral medicine in pill form, or is allergic to an ingredient in an existing medicine. Compounding pharmacies are also typically blocked from mass-producing their drugs. For weight-loss drugs, though, it has been a different story. After the US Food and Drug Administration (FDA) put semaglutide – marketed as the blockbuster obesity drug Wegovy – and tirzepatide – the same for Eli Lilly's Mounjaro – on the shortage list in 2022, compounders were allowed to ramp up production. 'It was almost like these companies found a loophole where they were allowed to do this on a mass scale,' says Field. The impact has been significant. At the start of this year, Novo Nordisk estimated that the copycat drugs accounted for around a third of the entire weight-loss market. That is despite warnings from the FDA about the health risks posed by compounded medicines, which do not have to be approved by the regulator. Beth, from Washington, says she was tempted by online ads for the compound medicines, having struggled with her weight since the pandemic. For her, the drugs helped her at a time when it seemed impossible to lose weight or stick to a diet. She dropped 30lbs over a few months of taking a compound weight-loss medicine. Others say they had little choice but to opt for compound versions, given that the branded medicines were too expensive and not covered by their health insurance. However, the situation is rapidly changing. Last month, the FDA banned mass production of copycat weight-loss treatments that use semaglutide, the ingredient in Novo Nordisk's Wegovy. It also removed tirzepatide from its shortage list last October. Novo Nordisk said the law has now made things clearer. 'Moving forward, any compounder that mass produces or sells knock-off drugs is breaking the law and compromising patient safety,' a spokesman said. Eli Lilly says the products 'pose potentially life-threatening health risks', adding: 'Patients shouldn't be exposed to risky, unapproved products when regulator-approved medicines are available.' Online medicines firms, also known as telehealth businesses, are now racing to find a way to continue getting cheaper, personalised replica drugs out to patients. Noom, a rival to Hims and Hers, has suggested it will still be able to sell compounded weight-loss drugs to patients under an exception set aside for 'personalised' medicines. Hims and Hers, meanwhile, has already struck a new deal with Novo to offer its branded obesity drug to patients. The US firm also said this month it was exploring expansion in the UK, after acquiring European rival Zava. Andrew Dudum, the Hims and Hers chief, suggested there could be 'expansive options in obesity that include that type of personalisation, or similar types', telling the Financial Times that it could sell replica obesity medicines in the UK and Europe. David Meinertz, the boss of Zava, agrees that there are opportunities for the business to grow outside of America. 'There's clearly the experience and expertise that Hims and Hers have built up in the US,' he says. 'But then we have things like the regulatory knowledge here in Zava, and this is where we combine our experiences and spearhead this effort.' Still, the situation in the UK is very different to the US. Here, the compounding pharmacy market is much smaller, with pharmacies able to prepare personalised medicines for patients if it is prescribed by a doctor. Elizabeth Philp, the co-founder of compounding pharmacy Roseway Labs, says there could be a role for more personalisation of medicines. 'The NHS will say wasted medication is one of their top issues – people who try medication, put it in their bathroom cupboard and never use it again because it didn't suit them,' she says. 'We can really help with that.' However, drug insiders argue it would be a 'very bad idea' if the UK started to think about bringing in cheaper compound medicines for weight loss. 'The real drugs are getting very cheap at volumes,' says one senior drug leader. 'Supply is not an issue.' It will be a message that Novo and Eli Lilly will seek to drum home as they seek to prevent smaller rivals from selling cheaper weight-loss medicines to patients. Still, the effects of this debate are already being felt by many in the US battling to lose weight. 'I cannot afford the full price at this time,' says Beth. 'I think it's awful that people are losing access to this medication due to finances or compounded meds going away. 'These drugs are literally life-changing.'